Subrata Majumdar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Subrata Majumdar has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Bidisha Paul Chowdhury
Division of Molecular Medicine, Bose Institute, Kolkata, India
10 shared publications- Sweta Ghosh
Department of Microbiology and Immunology, UofL-Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, USA
10 shared publications Junaid Jibran Jawed
Presidency Univ 2nd Campus, Inst Hlth Sci, Plot DG-02-02,Premises 14-0358,Act Area 1D Newtown, Kolkata 700156, West Bengal, India
9 shared publicationsKuntal Halder
Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal 700054, India
7 shared publications- Shibali Das
Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, Missouri, USA
7 shared publications Suchandra Bhattacharyya Majumdar
Division of Molecular Medicine Bose Institute Kolkata India
7 shared publications
Latest Publications
- 7 February 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 129, 111644
Myotubularin-related protein 6 is an ion channel-associated pro-leishmanial phosphatase
- 7 February 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 129, 111644
Myotubularin-related protein 6 is an ion channel-associated pro-leishmanial phosphatase
- 30 January 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 129, 111589
Myotubularin-related protein-6 silencing protects mice from Leishmania donovani infection
- 30 January 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 129, 111589
Myotubularin-related protein-6 silencing protects mice from Leishmania donovani infection
- 2 June 2022
- Published by Elsevier in Experimental Parasitology
- Vol. 239, 108286
Regulatory role of Transcription factor-EB (TFEB) in parasite control through alteration of antigen presentation in visceral leishmaniasis
- 2 June 2022
- Published by Elsevier in Experimental Parasitology
- Vol. 239, 108286
Regulatory role of Transcription factor-EB (TFEB) in parasite control through alteration of antigen presentation in visceral leishmaniasis
- 13 September 2021
- Published by Wiley in Molecular Carcinogenesis
- Vol. 60 (12) , 840-858
Crucial role of glucosylceramide synthase in the regulation of stem cell‐like cancer cells in B16F10 murine melanoma
Cancer stem cells render a complex cascade of events that facilitates highly invasive melanoma malignancy. Interplay between immunocytes and cancer stem cells within tumor microenvironment with the participation of sphingolipid signaling mediators skews the immune evasion strategies toward metastatic neoplasm. In this context, we aimed to explore the functional aspect of glucosylceramide synthase (GCS), a key enzyme of sphingolipid biosynthesis in the maintenance of melanoma stem cell‐like cancer cells (CSCs). Our findings demonstrated that tumor hypoxia was responsible for elevated GCS expression in melanoma, which was correlated with substantially increased melanoma CSCs. Moreover, hypoxia‐induced TGF‐β from TAMs and Tregs promoted GCS induction in B16F10 murine melanoma CSCs via PKCα signaling and facilitated the expansion of melanoma CSCs. Interestingly, GCS ablation hindered the immunosuppressiveness of TAMs and Tregs. Therefore, our study for the first time demonstrated a novel paracrine pathway of melanoma CSC maintenance and tumorigenicity, exploiting the bidirectional signaling with immunocytes. Furthermore, our study showed that the combinatorial immunotherapy involving immunomodulators like Mw and DTA‐1 repressed CSC pool affecting GCS functions in advanced‐stage B16F10 murine melanoma tumor. Moreover, GCS inhibition sensitized conventional chemotherapeutic drug‐resistant melanoma CSCs to the genotoxic drugs paving the way toward selective melanoma treatment. Better therapeutic efficacy with inhibition of GCS and CSC depletion suggests a crucial role of GCS in melanoma treatment, therefore, implying its application concerning clinical challenges of chemotherapy resistance leading to prolonged survival.
- 13 September 2021
- Published by Wiley in Molecular Carcinogenesis
- Vol. 60 (12) , 840-858
Crucial role of glucosylceramide synthase in the regulation of stem cell‐like cancer cells in B16F10 murine melanoma
Cancer stem cells render a complex cascade of events that facilitates highly invasive melanoma malignancy. Interplay between immunocytes and cancer stem cells within tumor microenvironment with the participation of sphingolipid signaling mediators skews the immune evasion strategies toward metastatic neoplasm. In this context, we aimed to explore the functional aspect of glucosylceramide synthase (GCS), a key enzyme of sphingolipid biosynthesis in the maintenance of melanoma stem cell‐like cancer cells (CSCs). Our findings demonstrated that tumor hypoxia was responsible for elevated GCS expression in melanoma, which was correlated with substantially increased melanoma CSCs. Moreover, hypoxia‐induced TGF‐β from TAMs and Tregs promoted GCS induction in B16F10 murine melanoma CSCs via PKCα signaling and facilitated the expansion of melanoma CSCs. Interestingly, GCS ablation hindered the immunosuppressiveness of TAMs and Tregs. Therefore, our study for the first time demonstrated a novel paracrine pathway of melanoma CSC maintenance and tumorigenicity, exploiting the bidirectional signaling with immunocytes. Furthermore, our study showed that the combinatorial immunotherapy involving immunomodulators like Mw and DTA‐1 repressed CSC pool affecting GCS functions in advanced‐stage B16F10 murine melanoma tumor. Moreover, GCS inhibition sensitized conventional chemotherapeutic drug‐resistant melanoma CSCs to the genotoxic drugs paving the way toward selective melanoma treatment. Better therapeutic efficacy with inhibition of GCS and CSC depletion suggests a crucial role of GCS in melanoma treatment, therefore, implying its application concerning clinical challenges of chemotherapy resistance leading to prolonged survival.
- 1 November 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 88, 106932
Glycyrrhizic acid facilitates anti-tumor immunity by attenuating Tregs and MDSCs: An immunotherapeutic approach
- 1 November 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 88, 106932
Glycyrrhizic acid facilitates anti-tumor immunity by attenuating Tregs and MDSCs: An immunotherapeutic approach
- 1 October 2020
- Published by Elsevier in Experimental Parasitology
- Vol. 217, 107948
Immunomodulator mediated changes in plasma membrane calcium ATPase in controlling visceral leishmaniasis
- 1 October 2020
- Published by Elsevier in Experimental Parasitology
- Vol. 217, 107948
Immunomodulator mediated changes in plasma membrane calcium ATPase in controlling visceral leishmaniasis
- 3 September 2020
- Published by Springer Nature in Molecular Biology Reports
- Vol. 47 (10) , 8101-8111
Cancer stem cells and ceramide signaling: the cutting edges of immunotherapy
The multipotent, self renewing “cancer stem cells” (CSCs), a small population within tumor microenvironment facilitates transformed cells to grow and propagate within the body. The CSCs are discovered as resistant to the chemotherapeutic drug with distinct immunological characteristics. In recent years, immunologically targeting CSCs have emerged as an integral part of effective and successful cancer therapy. CSCs notably exhibit dysregulation in conventional sub-cellular sphingolipid metabolism. Recently, ceramide decaying enzymes have been shown to activate alternative ceramide signaling pathways leading to reduction in efficacy of the chemotherapeutic drugs. Therefore, a control over ceramide mediated modulations of CSCs offers an attractive dimension of effective cancer treatment strategy in future. In this review, we focused on the recent findings on broad spectrum of ceramide mediated signaling in CSCs within the tumor niche and their role in potential cancer immunotherapy.
- 3 September 2020
- Published by Springer Nature in Molecular Biology Reports
- Vol. 47 (10) , 8101-8111
Cancer stem cells and ceramide signaling: the cutting edges of immunotherapy
The multipotent, self renewing “cancer stem cells” (CSCs), a small population within tumor microenvironment facilitates transformed cells to grow and propagate within the body. The CSCs are discovered as resistant to the chemotherapeutic drug with distinct immunological characteristics. In recent years, immunologically targeting CSCs have emerged as an integral part of effective and successful cancer therapy. CSCs notably exhibit dysregulation in conventional sub-cellular sphingolipid metabolism. Recently, ceramide decaying enzymes have been shown to activate alternative ceramide signaling pathways leading to reduction in efficacy of the chemotherapeutic drugs. Therefore, a control over ceramide mediated modulations of CSCs offers an attractive dimension of effective cancer treatment strategy in future. In this review, we focused on the recent findings on broad spectrum of ceramide mediated signaling in CSCs within the tumor niche and their role in potential cancer immunotherapy.
- RetractedOpen Access
- 31 August 2020
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 14 (8) , e0008575
RETRACTED: In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis
Background: Treatment failure and resistance to the commonly used drugs remains a major obstacle for successful chemotherapy against visceral leishmaniasis (VL). Since the development of novel therapeutics involves exorbitant costs, the effectiveness of the currently available antitrypanosomatid drug suramin has been investigated as an antileishmanial, specifically for VL, in vitro and in animal model experiments. Methodology/Principal: Leishmania donovani promastigotes were treated with suramin and studies were performed to determine the extent and mode of cell mortality, cell cycle arrest and other in vitro parameters. In addition, L . donovani infected BALB/c mice were administered suramin and a host of immunological parameters determined to estimate the antileishmanial potency of the drug. Finally, isothermal titration calorimetry (ITC) and enzymatic assays were used to probe the interaction of the drug with one of its putative targets namely parasitic phosphoglycerate kinase (LmPGK). Findings: The in vitro studies revealed the potential efficacy of suramin against the Leishmania parasite. This observation was further substantiated in the in vivo murine model, which demonstrated that upon suramin administration, the Leishmania infected BALB/c mice were able to reduce the parasitic burden and also generate the host protective immunological responses. ITC and enzyme assays confirmed the binding and consequent inhibition of LmPGK due to the drug. Conclusions/Significance: All experiments affirmed the efficacy of suramin against L . donovani infection, which could possibly lead to its inclusion in the repertoire of drugs against VL.
- 31 August 2020
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 14 (8) , e0008575
RetractedOpen AccessRETRACTED: In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis
Background: Treatment failure and resistance to the commonly used drugs remains a major obstacle for successful chemotherapy against visceral leishmaniasis (VL). Since the development of novel therapeutics involves exorbitant costs, the effectiveness of the currently available antitrypanosomatid drug suramin has been investigated as an antileishmanial, specifically for VL, in vitro and in animal model experiments. Methodology/Principal: Leishmania donovani promastigotes were treated with suramin and studies were performed to determine the extent and mode of cell mortality, cell cycle arrest and other in vitro parameters. In addition, L . donovani infected BALB/c mice were administered suramin and a host of immunological parameters determined to estimate the antileishmanial potency of the drug. Finally, isothermal titration calorimetry (ITC) and enzymatic assays were used to probe the interaction of the drug with one of its putative targets namely parasitic phosphoglycerate kinase (LmPGK). Findings: The in vitro studies revealed the potential efficacy of suramin against the Leishmania parasite. This observation was further substantiated in the in vivo murine model, which demonstrated that upon suramin administration, the Leishmania infected BALB/c mice were able to reduce the parasitic burden and also generate the host protective immunological responses. ITC and enzyme assays confirmed the binding and consequent inhibition of LmPGK due to the drug. Conclusions/Significance: All experiments affirmed the efficacy of suramin against L . donovani infection, which could possibly lead to its inclusion in the repertoire of drugs against VL.